<prompt> By binding RANKL with high affinity, which of the following drug reduces bone resorptionAlemtuzumabPalivizumabDaclizumabDenosumab  <response>: By binding to RANKL,denosumab inhibitsRANKL from activating its only receptor RANKon the surface of osteoclasts and their precursors. Prevention of RANKL-RANKinteraction inhibits osteoclast formation, function, and survival; thereby decreasing bone resorption and interrupting cancer-induced bone destruction Ref essentials of pharmacology, k. D tripati 5e 